MORE►
RA Capital
Illustration: Michael Samples
North Texas’ Secretome Therapeutics Raises $30M Series A to Advance Muscular Dystrophy-Related Drug
by Sandra Engelland | May 28, 2026
The financing from Boston's RA Capital Management will support company operations and the continued development of Secretome’s pipeline of innovative treatments, including STM-01, an nCPC-derived therapy in development for treating Duchenne muscular dystrophy, which has had few therapeutic options.
Related Articles
Biote Names Its Chief Financial and Business Officer as Interim CEO
Dallas-Based Apex Service Partners Gets Minority Investment From Apollo Funds
Align Capital Partners Acquires Idaho-Based Heritage Imaging
As World Cup Nears, Dallas-Based Topgolf Adds Some Soccer to Its Golf
EagleNXT Opens New HQ and Drone Manufacturing Center in North Texas
MORE►
Trending
North Texas is a big place, with plenty to do, see, hear, and watch. We scour the internet every week to find events and activities for you. As always, things may change at any time, so be sure to check the official website or registration page for the latest details....
Electric mobility is about more than battery range now. As EVs become part of everyday life, people want the experience to feel simple and reassuring, whether they are finding a charger, checking their vehicle status, making a payment, or getting help when they need it....
Plano-based Secretome Therapeutics, a biotech company advancing therapies derived from neonatal cardiac progenitor cells (nCPC), has announced the closing of $30 million in Series A financing from RA Capital Management, a multi-stage investment manager focused on public and private healthcare, life sciences, and planetary health companies....
“It’s critical that we increase awareness of the high prevalence of Alzheimer’s disease among adults with Down syndrome… ”
Melissa Petersen, Ph.D.
Associate Professor
UNT Health Fort Worth
.…on being UNT Health’s lead scientific investigator for the Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study....
UNT Health Fort Worth’s Institute for Translational Research is set to become the first site in Texas to join a national study on Alzheimer’s disease in adults with Down syndrome.
The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study, a national research initiative supported by the National Institutes of Health, studies how Alzheimer’s disease develops in adults with Down syndrome and aims to identify early biological markers of the disease....
Trending
North Texas is a big place, with plenty to do, see, hear, and watch. We scour the internet every week to find events and activities for you. As always, things may change at any time, so be sure to check the official website or registration page for the latest details....
Electric mobility is about more than battery range now. As EVs become part of everyday life, people want the experience to feel simple and reassuring, whether they are finding a charger, checking their vehicle status, making a payment, or getting help when they need it....
Plano-based Secretome Therapeutics, a biotech company advancing therapies derived from neonatal cardiac progenitor cells (nCPC), has announced the closing of $30 million in Series A financing from RA Capital Management, a multi-stage investment manager focused on public and private healthcare, life sciences, and planetary health companies....
“It’s critical that we increase awareness of the high prevalence of Alzheimer’s disease among adults with Down syndrome… ”
Melissa Petersen, Ph.D.
Associate Professor
UNT Health Fort Worth
.…on being UNT Health’s lead scientific investigator for the Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study....
UNT Health Fort Worth’s Institute for Translational Research is set to become the first site in Texas to join a national study on Alzheimer’s disease in adults with Down syndrome.
The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study, a national research initiative supported by the National Institutes of Health, studies how Alzheimer’s disease develops in adults with Down syndrome and aims to identify early biological markers of the disease....
